Cargando…

Ivermectin: does P-glycoprotein play a role in neurotoxicity?

The macrocyclic lactone ivermectin (Mectizan(®)) is widely used for the control of human filarial infections, particularly as a donated product for onchocerciasis and lymphatic filariasis. In the case of control of lymphatic filariasis in Africa, it is used in combination with donated albendazole. I...

Descripción completa

Detalles Bibliográficos
Autor principal: Edwards, Geoffrey
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2147658/
https://www.ncbi.nlm.nih.gov/pubmed/14975065
http://dx.doi.org/10.1186/1475-2883-2-S1-S8
_version_ 1782144491176591360
author Edwards, Geoffrey
author_facet Edwards, Geoffrey
author_sort Edwards, Geoffrey
collection PubMed
description The macrocyclic lactone ivermectin (Mectizan(®)) is widely used for the control of human filarial infections, particularly as a donated product for onchocerciasis and lymphatic filariasis. In the case of control of lymphatic filariasis in Africa, it is used in combination with donated albendazole. In areas co-endemic for Onchocerciasis and Loa loa, serious adverse reactions have been observed in patients with apparently high microfilaria counts of Loa loa. Recent findings suggest that the severe central nervous system side effects seen in various vertebrates following ivermectin treatment may be due to an absence of, or functional deficiency in P-glycoprotein. P-glycoprotein is expressed in the apical membrane of brain capillary epithelial cells and is responsible for limiting the brain penetration of a range of compounds. Toxicity of ivermectin in some collie dogs may be explained by a 4-bp deletion mutation of the mdr1 gene resulting in a frame shift, generating stop codons that prematurely terminate synthesis of P-glycoprotein. Additionally, sub-populations of CF-1 identified as expressing reduced levels of P-glycoprotein exhibit increased toxicity to substrates of this transporter. Furthermore, while the traditional view of drug-drug interactions is alteration in drug clearance mediated through a change in hepatic drug metabolism, some of these changes may arise through competition for binding sites on P-glycoprotein in the blood-brain barrier, resulting in reduced extracellular efflux and enhanced CNS toxicity. In conclusion, P-glycoprotein is an integral component of the human blood brain barrier and plays a central role in limiting drug uptake into the brain. Altered expression or function of p-glycoprotein could conceivably allow elevation of brain concentrations of ivermectin and produce severe neurotoxicity. This might arise through a genetic polymorphism in p-glycoprotein or co-administration of ivermectin with a drug or foodstuff that might inhibit this efflux transporter.
format Text
id pubmed-2147658
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-21476582007-12-20 Ivermectin: does P-glycoprotein play a role in neurotoxicity? Edwards, Geoffrey Filaria J Review The macrocyclic lactone ivermectin (Mectizan(®)) is widely used for the control of human filarial infections, particularly as a donated product for onchocerciasis and lymphatic filariasis. In the case of control of lymphatic filariasis in Africa, it is used in combination with donated albendazole. In areas co-endemic for Onchocerciasis and Loa loa, serious adverse reactions have been observed in patients with apparently high microfilaria counts of Loa loa. Recent findings suggest that the severe central nervous system side effects seen in various vertebrates following ivermectin treatment may be due to an absence of, or functional deficiency in P-glycoprotein. P-glycoprotein is expressed in the apical membrane of brain capillary epithelial cells and is responsible for limiting the brain penetration of a range of compounds. Toxicity of ivermectin in some collie dogs may be explained by a 4-bp deletion mutation of the mdr1 gene resulting in a frame shift, generating stop codons that prematurely terminate synthesis of P-glycoprotein. Additionally, sub-populations of CF-1 identified as expressing reduced levels of P-glycoprotein exhibit increased toxicity to substrates of this transporter. Furthermore, while the traditional view of drug-drug interactions is alteration in drug clearance mediated through a change in hepatic drug metabolism, some of these changes may arise through competition for binding sites on P-glycoprotein in the blood-brain barrier, resulting in reduced extracellular efflux and enhanced CNS toxicity. In conclusion, P-glycoprotein is an integral component of the human blood brain barrier and plays a central role in limiting drug uptake into the brain. Altered expression or function of p-glycoprotein could conceivably allow elevation of brain concentrations of ivermectin and produce severe neurotoxicity. This might arise through a genetic polymorphism in p-glycoprotein or co-administration of ivermectin with a drug or foodstuff that might inhibit this efflux transporter. BioMed Central 2003-10-24 /pmc/articles/PMC2147658/ /pubmed/14975065 http://dx.doi.org/10.1186/1475-2883-2-S1-S8 Text en
spellingShingle Review
Edwards, Geoffrey
Ivermectin: does P-glycoprotein play a role in neurotoxicity?
title Ivermectin: does P-glycoprotein play a role in neurotoxicity?
title_full Ivermectin: does P-glycoprotein play a role in neurotoxicity?
title_fullStr Ivermectin: does P-glycoprotein play a role in neurotoxicity?
title_full_unstemmed Ivermectin: does P-glycoprotein play a role in neurotoxicity?
title_short Ivermectin: does P-glycoprotein play a role in neurotoxicity?
title_sort ivermectin: does p-glycoprotein play a role in neurotoxicity?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2147658/
https://www.ncbi.nlm.nih.gov/pubmed/14975065
http://dx.doi.org/10.1186/1475-2883-2-S1-S8
work_keys_str_mv AT edwardsgeoffrey ivermectindoespglycoproteinplayaroleinneurotoxicity